Lilly Raises Profit Forecast on Amylin's $1.26B Payment

Source: Reuters, Toni Clarke and Esha Dey (8/9/12)

"Lilly plans to use the cash to advance its 'pipeline of more than 60 potential new medicines,' among other corporate uses."

Reuters, Toni Clarke and Esha Dey

Eli Lilly and Co (LLY.N) raised its 2012 net profit forecast for the second time in as many weeks to reflect an early payment of $1.26 billion from former partner Amylin Pharmaceuticals Inc, which has been acquired by Bristol-Myers Squibb Co (BMY.N).

Diabetes specialist Amylin had ended its decade-long partnership with Lilly in November. The companies were partners in marketing Amylin's diabetes drug Byetta and its longer-acting version, Bydureon. Bristol, which completed its Amylin purchase on Wednesday, has paid $1.7 billion apart from the cash consideration to cover Amylin's debt and its obligations to Eli Lilly.

Lilly plans to use the cash to advance its "pipeline of more than 60 potential new medicines," among other corporate uses. . .View Full Article

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
Source: Streetwise Reports (06/27/2026)

Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.

uniQure Epilepsy Gene Therapy Data Draws Investor Focus
Source: Streetwise Reports (06/26/2026)

uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.

Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth
Source: Streetwise Reports (06/20/2026)

Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.

Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.